Mounjaro vs Wegovy in India 2026: Cost, Results & Which to Choose

Quick answer: In India in 2026, Mounjaro (tirzepatide) produces slightly greater average weight loss — up to ~20–22% versus ~15% for Wegovy (semaglutide) — but Wegovy is now far cheaper after generic semaglutide arrived in March 2026. Mounjaro costs roughly ₹13,125–₹25,781/month; generic semaglutide runs about ₹1,300–₹4,200/month. The right choice depends on your clinical profile, tolerance and budget — and a doctor should decide.

What's the difference between Mounjaro and Wegovy?

Both are once-weekly GLP-1 injections, but they aren't the same molecule. Wegovy contains semaglutide and acts on a single receptor (GLP-1). Mounjaro contains tirzepatide and is a dual agonist — it activates both GIP and GLP-1 receptors, which appears to drive stronger metabolic effects for many people.

How much weight can you lose on each?

In the SURMOUNT-1 trial, tirzepatide produced up to ~20–22% average body-weight loss over 72 weeks at the highest dose. In the STEP 1 trial, semaglutide produced about 15% over 68 weeks. Both were combined with diet and activity changes, and individual results vary — dose, consistency, protein intake and strength training all matter.

Which is cheaper in India in 2026?

This is where the picture flipped. Semaglutide's Indian patent expired on 20 March 2026, and 40+ generics launched — dropping Wegovy-equivalent costs to roughly ₹1,300–₹4,200/month, with branded Wegovy itself cut by up to 48%. Tirzepatide remains patent-protected until ~2036, so Mounjaro has no generic competition yet and stays pricier. For full pricing, see our Mounjaro cost in India guide and generic semaglutide guide.

Side effects: are they different?

Both share the same main side effects — nausea, vomiting, diarrhoea and constipation — usually strongest early and easing within weeks. Slow dose titration reduces them. Both carry a boxed warning for thyroid C-cell tumours and rare risks like pancreatitis, so a clinician must screen your history first.

So which should you choose?

If maximum weight loss is the priority and budget allows, tirzepatide has a slight edge in trials. If affordability matters most, generic semaglutide now delivers strong results at a fraction of the cost. There's no universal winner — your doctor weighs your BMI, conditions, tolerance and goals. Start with a free eligibility check or read the complete GLP-1 guide for India.

"For most patients the question isn't 'which is stronger' — it's which one they'll tolerate and afford for 12–18 months. Adherence beats theoretical potency." — MetaFit Medical Team